{"disease":{"id":"agammaglobulinemia","name":"agammaglobulinemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05321407","title":"COVID-19 Vaccine Responses in PIDD Subjects","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06954441","title":"V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","has_results":false},{"nct_id":"NCT01581593","title":"Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Kedrion S.p.A.","has_results":true},{"nct_id":"NCT00161993","title":"Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}